Literature DB >> 3339951

Study of digoxin as inhibitor of the in vivo effects of acetyl glyceryl ether phosphorylcholine (AGEPC) in mice.

D Kelefiotis1, E Lanara, C Vakirtzi-Lemonias, A Siafaka, M Mavris, M Lazanas, C A Demopoulos.   

Abstract

Acetyl glyceryl ether phosphorylcholine (AGEPC) and the cardiac glycoside digoxin were administered intravenously through the tail vein into ether-anesthetized SWR mice (two months old). The administered doses were 0.18 nmol AGEPC/g b.w. (a lethal one) and 75 or 125 ng digoxin/b.w. Digoxin ameliorates the effects of the lethal dose of AGEPC showing maximum activity when given 5 or 10 min after AGEPC administration to female and male animals respectively. Digoxin shows also a protective action towards the effects of AGEPC and maximum activity appears when it is given 10 min before AGEPC administration. In agreement with the picture of increased survival in digoxin pretreated animals, are our findings on life prolongation of mice which finally die from AGEPC, the amelioration of the expected fall in blood platelet counts after AGEPC administration as well as the improved performance of the animals in a series of physical tests.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3339951     DOI: 10.1016/0024-3205(88)90453-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

Review 1.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

2.  In vivo responses of mouse blood cells to platelet-activating factor (PAF): role of the mediators of anaphylaxis.

Authors:  D Kelefiotis; C Vakirtzi-Lemonias
Journal:  Agents Actions       Date:  1993-11

Review 3.  A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?

Authors:  Vasiliki D Papakonstantinou; Nefeli Lagopati; Effie C Tsilibary; Constantinos A Demopoulos; Athanassios I Philippopoulos
Journal:  Bioinorg Chem Appl       Date:  2017-03-28       Impact factor: 7.778

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.